Investors can contact the law firm at no cost to learn more about recovering their losses
LOS ANGELES, Feb. 10, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Immunovant, Inc. ("Immunovant" or the "Company") (NASDAQ: IMVT) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors. The investigation focuses on whether Immunovant issued misleading and/or false statements and/or failed to disclose information pertinent to investors.
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
On February 2, 2021, Immunovant announced a “voluntary pause of dosing in its ongoing clinical trials for IMVT-1401”. Immunovant admitted that it "has become aware of a physiological signal consisting of elevated total cholesterol and LDL levels in IMVT-1401-treated patients" and “out of an abundance of caution, the Company has decided to voluntarily pause dosing in ongoing clinical studies in both TED and in Warm Autoimmune Hemolytic Anemia, in order to inform patients, investigators, and regulators as well as to modify the monitoring program." Shares of Immunovant fell by more than 42% on the same day, based on this news.
Please visit our website to review more information and submit your transaction information.
The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
lesley@portnoylaw.com
310-692-8883
www.portnoylaw.com
Attorney Advertising